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Heart failure has been known as an increasing 
health burden worldwide and the prevalence 
is expected to rise more than 23 million in 
2030. Chronic heart failure has characteristic 
of ventricular dysfunction which will cause 
dyspnea, fatique, and finally some limitation in 
functional capacity and reduced quality of life.1
Recent advances in treatment of chronic 
heart failure may give us option of wide variety 
of modalities from pharmacologic and non-
pharmacologic therapy with invasive and non-
invasive approaches. Each has its own benefit 
and risk. Structural heart disease of heart failure 
indicates non reversible damage. Thus, treatment 
will aim to prevent symptoms and improve quality 
of life. Enhanced external counterpulsation 
(EECP) was a non-invasive treatment originally 
to reduce symptom of refractory angina.2-4 In the 
newest European Society of Cardiology (ESC) 
guideline for management of stable coronary 
artery disease 2013, EECP had been approved as 
class IIa-recommended treatment for refractory 
angina.5 Enhanced external counterpulsation 
(EECP) had been reported to improve myocardial 
contractility, increased stroke volume, enhanced 
angiogenesis and developing new collateral 
circulation. EECP produces pulsatile blood 
circulation which will increase endothelial shear 
stress and, thus, improved endothelial function. 
Some patients with ischemic heart disease and 
not eligible to have revascularization therapy 
due to increased risk may have recurrent angina 
symptom and shortness of breath. These patients 
are assumed to be good candidates for EECP 
therapy.6
Actually, EECP is not a novel therapy. 
Since almost two decades ago EECP was given 
to patients with chronic heart failure on top 
of optimal pharmacologic therapy, not only 
to those with concomitant refractory angina 
pectoris. Some studies showed beneficial effect 
of EECP in heart failure but its efficacy is 
still controversial. The randomized controlled 
Prospective Evaluation of EECP in congestive 
heart failure (PEECH) trial involved 187 patients 
of ischemic and non-ischemic heart failure 
showed significant improvement in exercise 
tolerance but failed to show significant change 
in maximal oxygen uptake after six months post 
treatment.7 Result from PEECH trial had been 
considered due to the placebo effect or training 
effect. The Multicentre study of EECP (MUST-
EECP) and other similar studies showed that 
EECP is safe and effective for chronic heart 
failure.8-10 The data from International EECP 
Patient Registry (IEPR) of 1097 patients with 
angina symptoms who were mostly not eligible 
for further revascularization therapy. Although 
there were significant improvement in symptoms, 
but the incidence of major adverse cardiac event 
(MACE) still high in the long term. It seemed 
that EECP could not modify disease process.11
A double-blind randomized clinical trial 
by Rampengan et al12 in this journal tried to 
investigate the efficacy EECP in improving 
functional capacity in chronic ischemic heart 
failure. There were 99 patients involved and 
significant improvement was shown in the 
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EECP group. The result is in accordance with 
some studies of EECP, but its efficacy in the 
long term remains unknown.13 The newest 
guidelines for management of heart failure 2013 
had not yet mentioned EECP for heart failure 
treatment.14,15 However, it had been showed 
beneficial effect of ECCP in selected patients 
specially chronic heart failure with ischemic 
origin or refractory angina. Clinical benefit from 
EECP including reduced symptom, reduced re-
hospitalization and reduced health cost.16 Will 
EECP be recommended for chronic heart failure 
in the next guideline? Larger, longer and further 
studies on EECP in heart failure will certainly be 
needed. Meanwhile, patients who will have most 
benefit of EECP therapy must be well-selected. 
Alternative treatment options are widely open for 
the best therapy suitable for patients.
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